EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Incidence, Severity and Risk Factors of Renal Injury in Lung Cancer Patients Receiving Osimertinib Therapy: A Real‐World Study

Jieshan Lin iD, Xiaoying Dong, Wenfang Tang, Shuangxin Liu

Cancer Medicine · 2025

DOI: 10.1002/cam4.71382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Jieshan Lin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Gua…. Hauptthemen laut MEDLINE: Acrylamides, Lung Neoplasms, Aniline Compounds, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Project of National Natural Science Foundation of China, the Zhongshan Science and Technology Bureau Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The high burden of lung cancer in developing countries has led to the widespread use of EGFR inhibitors like osimertinib. However, little is known about the prevalence and risk factors of renal injury associated with osimertinib use. Therefore, this study aims to investigate the incidence, severity and risk factors of renal injury in patients receiving osimertinib in the real world.

Methods

We retrospectively analyzed 1138 patients with lung cancer treated with osimertinib. Renal injury was defined as an estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m 2 and/or the presence of proteinuria. Multivariable logistic regression models were used to identify independent risk factors for renal injury.

Results

Totally, 215 (18.89%) patients developed renal injury during follow‐up. Most cases of renal injury were transient (149/1138, 13.09%), while sustained renal injury accounted for 5.8% (66/1138) of the total cohort. Impaired renal function (eGFR < 60 mL/min/1.73m 2 ) was observed in 136 (11.95%) patients, predominantly at a moderate stage (eGFR 30–59), and proteinuria was present in 100 (8.79%) patients, primarily of mild severity. Among patients with renal injury, 73.53% had a mild creatinine elevation (< 50% increase from baseline). Moreover, the mean time to renal injury onset was 7.92 months (SD 8.34), with a mean recovery time of 4.21 months (SD 6.31). Importantly, age ≥ 60 years (OR = 2.307, 95% CI: 1.348–3.947, p = 0.002) and baseline renal injury (OR = 20.942, 95% CI: 8.398–52.223, p < 0.001) were significant independent risk factors for sustained renal injury.

Conclusions

This study demonstrates that renal injury is not rare in lung cancer patients treated with osimertinib, particularly in patients aged ≥ 60 years or with pre‐existing renal injury. Although most cases are reversible, regular monitoring of renal function is strongly recommended for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesLung NeoplasmsAniline CompoundsAntineoplastic AgentsAcute Kidney InjuryHumansFemaleMaleRisk FactorsIncidenceMiddle AgedAgedRetrospective StudiesGlomerular Filtration RateSeverity of Illness IndexProteinuriaAdultAged, 80 and overIndolesPyrimidines

Stichwörter der Autor:innen

lung cancerosimertinibrenal injury

Substanzen

osimertinibAcrylamidesAniline CompoundsAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, P. R. China.
  • Department of Nephrology, Blood Purification Center, Zhongshan City People's Hospital, Zhongshan, Guangdong, P. R. China.
  • School of Medicine, South China University of Technology, Guangzhou, Guangdong, P. R. China.
  • Department of Cardiothoracic Surgery, Zhongshan City People's Hospital, Zhongshan, Guangdong, P. R. China.
  • Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, P. R. China.

ORCID-Profile: Jieshan Lin

Förderung

  • the Project of National Natural Science Foundation of China
  • the Zhongshan Science and Technology Bureau Project

Zitieren

APA

Lin, J., Dong, X., Tang, W., & Liu, S. (2025). The Incidence, Severity and Risk Factors of Renal Injury in Lung Cancer Patients Receiving Osimertinib Therapy: A Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.71382

Vancouver

Lin J, Dong X, Tang W, Liu S. The Incidence, Severity and Risk Factors of Renal Injury in Lung Cancer Patients Receiving Osimertinib Therapy: A Real‐World Study. Cancer Medicine. 2025. doi:10.1002/cam4.71382

BibTeX
@article{Lin2025,
  author = {Lin, Jieshan and Dong, Xiaoying and Tang, Wenfang and Liu, Shuangxin},
  title = {The Incidence, Severity and Risk Factors of Renal Injury in Lung Cancer Patients Receiving Osimertinib Therapy: A Real‐World Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71382}
}
Kostenlos starten →